Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...

CHICAGO, March 5, 2026 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone ...

A pulmonary embolism is a blood clot that blocks blood flow to an artery in the lung, according to the Mayo Clinic. This is considered a medical emergency as it causes issues with blood flow and ...

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...

“She never wanted anyone to have to naively be in pain without answers," Dern tells PEOPLE of her mother, who died in November 2025 Bailey Richards is a Writer-Reporter at PEOPLE. She has been working ...

Pulmonary fibrosis is a type of interstitial lung disease (ILD) characterized by fibrous scarring of the lungs. 1 The most common type of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), ...

Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic ...

Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, ...